| 基因名 | 疾病 | 靶向药 | 化疗药 | 基因突变 | 临床解释 |
|---|---|---|---|---|---|
| MX1 | 0 | 0 | |||
| MYADM | 0 | 0 | |||
| MYB | 急性嗜碱性白血病,小儿低级别胶质瘤（PLGG） | 2 | 2 | ||
| MYBL1 | 0 | 0 | |||
| MYBL2 | 0 | 0 | |||
| MYC | 食管癌,小细胞肺癌,髓母细胞瘤,多发性骨髓瘤 | 伊布替尼,JQ1,奥拉帕利,Prexasertib, | 顺铂, | 2 | 4 |
| MYCL | 多发性骨髓瘤 | GSK1210151A,JQ1, | 1 | 1 | |
| MYCN | 髓母细胞瘤,神经母细胞瘤 | CBL0137,GSK126,JQ1,JQEZ5,比拉瑞塞,帕比司他,索尼德吉, | 三氧化二砷, | 1 | 8 |
| MYCNOS | 0 | 0 | |||
| MYD88 | 乳腺癌,慢性淋巴细胞白血病,华登斯特巨球蛋白血症 | 伊布替尼,IMG-2005-5,IRAK-1/4 Inhibitor, | 紫杉醇, | 2 | 4 |
| MYH10 | 0 | 0 | |||
| MYH11 | 0 | 0 | |||
| MYH14 | 0 | 0 | |||
| MYH9 | 0 | 0 | |||
| MYO10 | 0 | 0 | |||
| MYO18A | 0 | 0 | |||
| MYO1B | 0 | 0 | |||
| MYO3A | 0 | 0 | |||
| MYOD1 | 0 | 0 | |||
| MYOF | 0 | 0 | |||
| MYSM1 | 0 | 0 | |||
| NAB1 | 0 | 0 | |||
| NAB2 | 0 | 0 | |||
| NABP2 | 0 | 0 | |||
| NAP1L1 | 0 | 0 | |||
| NAPRT | 癌症 | GNE-617, | 1 | 1 | |
| NAT1 | 0 | 0 | |||
| NAT2 | 0 | 0 | |||
| NAV3 | 0 | 0 | |||
| NBN | 头颈癌 | GPI-15427, | 1 | 1 | |
| NBPF1 | 0 | 0 | |||
| NCAM1 | 0 | 0 | |||
| NCAM2 | 0 | 0 | |||
| NCF2 | 0 | 0 | |||
| NCF4 | 0 | 0 | |||
| NCK1 | 0 | 0 | |||
| NCOA2 | 间充质软骨肉瘤 | 1 | 6 | ||
| NCOA3 | 乳腺癌 | 2 | 2 | ||
| NCOA4 | 0 | 0 | |||
| NCOA6 | 0 | 0 | |||
| NCOR1 | 0 | 0 | |||
| NCOR2 | 0 | 0 | |||
| NCSTN | 0 | 0 | |||
| NDRG1 | 0 | 0 | |||
| NDUFA13 | 0 | 0 | |||
| NDUFB11 | 0 | 0 | |||
| NDUFS1 | 0 | 0 | |||
| NEB | 0 | 0 | |||
| NEDD9 | 肝细胞癌 | 1 | 1 | ||
| NEGR1 | 0 | 0 | |||
| NEIL1 | 0 | 0 | |||
| NEIL2 | 0 | 0 | |||
| NEIL3 | 0 | 0 | |||
| NEK11 | 0 | 0 | |||
| NEO1 | 0 | 0 | |||
| NF1 | 非小细胞肺癌,周围神经鞘恶性肿瘤,黑色素瘤,神经母细胞瘤,神经纤维瘤,丛状神经纤维瘤,皮肤黑色素瘤 | AZ628,比美替尼、贝美替尼,达拉非尼,JQ1 Compound,PD0325901,西罗莫司,司美替尼,曲美替尼,维莫非尼,VX-11e, | 4 | 12 | |
| NF2 | 听神经瘤,乳腺癌,腹膜间皮瘤,甲状腺癌 | 依维莫司,司美替尼,西罗莫司, | 卡铂,顺铂, | 4 | 4 |
| NFATC2 | 0 | 0 | |||
| NFATC4 | 0 | 0 | |||
| NFE2L1 | 0 | 0 | |||
| NFE2L2 | 0 | 0 | |||
| NFE2L3 | 0 | 0 | |||
| NFKB1 | 0 | 0 | |||
| NFKBIA | 0 | 0 | |||
| NFXL1 | 0 | 0 | |||
| NHEJ1 | 0 | 0 | |||
| NIN | 0 | 0 | |||
| NKAP | 0 | 0 | |||
| NKX2-1 | 0 | 0 | |||
| NKX2-4 | 0 | 0 | |||
| NKX3-1 | 0 | 0 | |||
| NLGN1 | 0 | 0 | |||
| NLRC3 | 0 | 0 | |||
| NLRP1 | 0 | 0 | |||
| NLRP3 | 0 | 0 | |||
| NLRP5 | 0 | 0 | |||
| NLRP7 | 0 | 0 | |||
| NOD1 | 0 | 0 | |||
| NONO | 0 | 0 | |||
| NOS2 | 0 | 0 | |||
| NOS3 | 0 | 0 | |||
| NOTCH1 | 急性T细胞白血病,成人T细胞白血病,慢性淋巴细胞白血病,结直肠癌,头颈鳞状细胞癌,非小细胞肺癌,套细胞淋巴瘤 | LGK974,NOTCH1 Antibody,PF-03084014, | 泼尼松, | 19 | 25 |
| NOTCH2 | 0 | 0 | |||
| NOTCH3 | 胰腺癌,直肠癌 | 他瑞妥单抗, | 1 | 2 | |
| NOTCH4 | 0 | 0 | |||
| NPM1 | 急性髓性白血病 | All-trans Retinoic Acid,Anti-CD123,Anti-CD33,Induction Therapy,NSC348884, | 柔红霉素,丙戊酸钠, | 2 | 34 |
| NQO1 | 肺癌 | 氨柔比星, | 2 | 2 | |
| NR1I2 | 0 | 0 | |||
| NR1I3 | 0 | 0 | |||
| NR2F2 | 结直肠癌 | 1 | 1 | ||
| NR3C1 | 0 | 0 | |||
| NR3C2 | 0 | 0 | |||
| NR4A2 | 0 | 0 | |||
| NR4A3 | 0 | 0 | |||
| NRAS | 急性髓性白血病,癌症,结直肠癌,滤泡性甲状腺癌,头颈部鳞状细胞癌,非小细胞肺癌,恶性胸膜间皮瘤,黑色素瘤,多发性骨髓瘤,神经母细胞瘤,皮肤黑色素瘤,甲状腺癌 | Tanespimycin,Amuvatinib,Dactolisib,比美替尼、贝美替尼,西妥昔单抗,达拉非尼,厄洛替尼,依维莫司,伊匹单抗,二甲双胍,Omipalisib,帕尼单抗,瑞博西尼,RO4987655,司美替尼,替莫唑胺,曲美替尼,维莫非尼, | 多西他赛, | 18 | 103 |
| NRG1 | 乳腺癌,癌症,胆管癌,结直肠癌,头颈部鳞状细胞癌,肺腺癌,非小细胞肺癌,粘液腺癌,卵巢癌,胰腺腺癌 | 阿法替尼,Anti-ERBB3 Agents,AV-203,西妥昔单抗,厄洛替尼,帕妥珠单抗,GSK2849330,拉帕替尼,Patritumab, | 卡铂,顺铂,吉西他滨,紫杉醇, | 5 | 13 |
| NRG3 | 0 | 0 | |||
| NRP2 | 0 | 0 | |||
| NRXN1 | 0 | 0 | |||
| NSD1 | 0 | 0 | |||
| NSD2 | 0 | 0 | |||
| NSD3 | 0 | 0 | |||
| NT5C2 | 急性淋巴细胞白血病,T细胞急性淋巴细胞白血病 | Arabinosylguanine, | 巯嘌呤,硫鸟嘌呤,奈拉滨, | 3 | 8 |
| NT5E | 结直肠癌 | 西妥昔单抗, | 1 | 1 | |
| NTHL1 | 0 | 0 | |||
| NTM | 0 | 0 | |||
| NTRK1 | 癌症,胆管癌,结直肠癌,脂纤维瘤样神经肿瘤,肺腺癌,非小细胞肺癌,黑色素瘤,神经母细胞瘤,胰腺癌,小儿纤维肉瘤,肉瘤,实体瘤 | 拉罗替尼,克唑替尼,恩曲替尼,拉罗替尼,Lestaurtinib (CEP-701),Selitrectinib, | 12 | 28 | |
| NTRK2 | 血液癌,细胞星形细胞瘤,肉瘤 | 拉罗替尼, | 3 | 3 | |
| NTRK3 | 乳腺癌,乳腺分泌癌,癌症,先天性纤维肉瘤,血液癌,髓母细胞瘤,乳头状甲状腺癌,小儿B细胞淋巴母细胞白血病,小儿B淋巴细胞白血病,小儿纤维肉瘤,唾液腺癌,实体瘤 | 克唑替尼,恩曲替尼,拉罗替尼,拉罗替尼,Selitrectinib,PLX7486, | 7 | 17 | |
| NUBPL | 0 | 0 | |||
| NUDT1 | 0 | 0 | |||
| NUDT18 | 0 | 0 | |||
| NUF2 | 0 | 0 | |||
| NUMA1 | 0 | 0 | |||
| NUP107 | 0 | 0 | |||
| NUP210 | 0 | 0 | |||
| NUP85 | 0 | 0 | |||
| NUP93 | 0 | 0 | |||
| NUP98 | 急性髓性白血病 | 1 | 1 | ||
| NUTM1 | 0 | 0 | |||
| NUTM2A | 0 | 0 | |||
| NYAP2 | 0 | 0 | |||
| OBSCN | 0 | 0 | |||
| OBSL1 | 0 | 0 | |||
| OGDH | 0 | 0 | |||
| OMD | 0 | 0 | |||
| OPCML | 0 | 0 | |||
| OPRM1 | 0 | 0 | |||
| OR11G2 | 0 | 0 | |||
| OR2T4 | 0 | 0 | |||
| OR4A15 | 0 | 0 | |||
| OR4C6 | 0 | 0 | |||
| OR5L2 | 0 | 0 | |||
| OR6F1 | 0 | 0 | |||
| OSBPL9 | 0 | 0 | |||
| OTOS | 0 | 0 | |||
| P2RY8 | 0 | 0 | |||
| P4HB | 0 | 0 | |||
| PABPC1 | 0 | 0 | |||
| PABPC3 | 0 | 0 | |||
| PAG1 | 0 | 0 | |||
| PAK1 | 0 | 0 | |||
| PAK3 | 0 | 0 | |||
| PAK5 | 0 | 0 | |||
| PAK6 | 0 | 0 | |||
| Pak7 | 0 | 0 | |||
| PALB2 | 乳腺癌,胰腺癌,前列腺癌 | 丝裂霉素C,奥拉帕利, | 2 | 3 | |
| PALLD | 0 | 0 | |||
| PAPOLG | 0 | 0 | |||
| PAPPA2 | 肺腺癌 | 派姆单抗（帕博利珠单抗）, | 1 | 1 | |
| PAQR8 | 0 | 0 | |||
| PARK2 | 0 | 0 | |||
| PARP1 | 周围神经鞘恶性肿瘤 | 奥拉帕利, | 1 | 1 | |
| PARP2 | 0 | 0 | |||
| PARP3 | 0 | 0 | |||
| PARP4 | 0 | 0 | |||
| PASK | 0 | 0 | |||
| PAX3 | 0 | 0 | |||
| PAX5 | 小儿B淋巴细胞白血病 | 1 | 2 | ||
| PAX7 | 0 | 0 | |||
| PAX8 | 女性生殖器官癌 | 2 | 2 | ||
| PBK | 胃腺癌,非小细胞肺癌 | 吉非替尼, | 2 | 2 | |
| PBLD | 肝细胞癌 | 1 | 1 | ||
| PBRM1 | 透明细胞肾细胞癌,肾细胞癌 | 阿特朱单抗，阿替利珠单抗,阿维单抗 巴文西亚,度伐利尤单抗，德瓦鲁单抗,CTLA-4 Inhibitor,依维莫司,伊匹单抗,PD-L1 Antibody,派姆单抗（帕博利珠单抗）,纳武单抗（纳武利尤单抗）, | 2 | 5 | |
| PBX1 | 0 | 0 | |||
| PC | 0 | 0 | |||
| PCBP1 | 0 | 0 | |||
| PCDH10 | 0 | 0 | |||
| PCDH17 | 0 | 0 | |||
| PCDH18 | 0 | 0 | |||
| PCDH9 | 0 | 0 | |||
| PCK1 | 0 | 0 | |||
| PCLO | 0 | 0 | |||
| PCSK6 | 0 | 0 | |||
| PCSK7 | 0 | 0 | |||
| PDCD1 | 0 | 0 | |||
| PDCD11 | 0 | 0 | |||
| PDCD1LG2 | 头颈癌 | 派姆单抗（帕博利珠单抗）, | 1 | 1 | |
| PDCD4 | 肺癌 | 紫杉醇, | 1 | 1 | |
| PDE11A | 0 | 0 | |||
| PDE1C | 0 | 0 | |||
| PDE3A | 0 | 0 | |||
| PDE4D | 0 | 0 | |||
| PDE4DIP | 0 | 0 | |||
| PDE6C | 0 | 0 | |||
| PDGFB | 小儿B淋巴细胞白血病 | 达沙替尼,伊马替尼, | 1 | 1 | |
| PDGFRA | 癌症,慢性骨髓单核细胞白血病,胃肠道间质瘤,非小细胞肺癌,黑色素瘤,骨髓和淋巴肿瘤伴嗜酸性粒细胞增多和pdgfra,pdgfrb和fgfr1异常 | Crenolanib,达沙替尼,伊马替尼,Imatinib Mesylate,帕纳替尼/普纳替尼/波纳替尼,舒尼替尼, | 21 | 45 | |
| PDGFRB | 急性淋巴细胞白血病,成人B淋巴细胞白血病,慢性骨髓单核细胞白血病,慢性骨髓增生性疾病,血液学癌症,小儿B细胞急性淋巴细胞白血病,小儿B细胞淋巴细胞白血病 | 巴非替尼,CHZ868,达沙替尼,伊马替尼,尼洛替尼,帕纳替尼/普纳替尼/波纳替尼,Rebastinib, | 4 | 11 | |
| PDHA2 | 0 | 0 | |||
| PDILT | 0 | 0 | |||
| PDK1 | 0 | 0 | |||
| PDPK1 | 0 | 0 | |||
| PDPN | 0 | 0 | |||
| PDYN | 0 | 0 | |||
| PDZRN3 | 0 | 0 | |||
| PEG3 | 0 | 0 | |||
| PER1 | 0 | 0 | |||
| PGBD1 | 0 | 0 | |||
| PGR | 乳腺癌 | 依西美坦, | 他莫昔芬, | 1 | 4 |
| PH0X2B | 0 | 0 | |||
| PHF1 | 0 | 0 | |||
| PHF20L1 | 0 | 0 | |||
| PHF6 | 0 | 0 | |||
| PHF7 | 0 | 0 | |||
| PHLPP2 | 0 | 0 | |||
| PHOX2B | 0 | 0 | |||
| PIBF1 | 0 | 0 | |||
| PIGF | 0 | 0 | |||
| PIK3C2A | 0 | 0 | |||
| PIK3C2B | 0 | 0 | |||
| PIK3C2G | 0 | 0 | |||
| PIK3C3 | 0 | 0 | |||
| PIK3CA | 乳腺癌,癌症,宫颈癌,结直肠癌,子宫内膜癌,上皮性卵巢癌,雌激素受体阳性乳腺癌,胃腺癌,多形性胶质母细胞瘤,头颈癌,头颈鳞状细胞癌,HER2受体阳性乳腺癌,侵袭性管状乳腺癌,lunG腺癌,非小细胞肺癌,黑色素瘤,默克尔细胞癌,胃癌,甲状腺癌 | Tanespimycin,Ado-trastuzumab,阿法替尼,阿培利司,Anti-EGFR Monoclonal Antibody,Apitolisib,阿司匹林,Capivasertib,贝伐单抗,Dactolisib,Buparlisib,卡博替尼,Celecoxib,西妥昔单抗,CH5132799,厄洛替尼,依维莫司,氟维司群,吉非替尼,布洛芬,艾代拉里斯,拉帕替尼,MK-2206,Dactolisib,哌柏西利,帕博西尼,帕博西林,帕尼单抗,Perifosine,PI103,PI3K Inhibitor,Pictilisib,Torkinib,Radiation,西罗莫司,瑞戈非尼,瑞博西尼,Ridaforolimus,Taselisib,曲美替尼,曲妥珠单抗,维莫非尼, | 氟尿嘧啶,顺铂,环磷酰胺,多柔比星,表柔比星,伊立替康,奥沙利铂,紫杉醇,舒林酸,他莫昔芬, | 40 | 265 |
| PIK3CB | 0 | 0 | |||
| PIK3CD | 0 | 0 | |||
| PIK3CG | 0 | 0 | |||
| PIK3R1 | 乳腺癌,多形性胶质母细胞瘤 | Buparlisib,Torkinib, | 1 | 2 | |
| PIK3R2 | 黑色素瘤 | 维莫非尼, | 2 | 2 | |
| PIK3R3 | 0 | 0 | |||
| PIM1 | 非小细胞肺癌 | 1 | 1 | ||
| PIP5K1A | 0 | 0 | |||
| PKD1L2 | 0 | 0 | |||
| PKD2 | 0 | 0 | |||
| PKHD1 | 0 | 0 | |||
| PLA2G1B | 0 | 0 | |||
| PLAC8 | 0 | 0 | |||
| PLAG1 | 0 | 0 | |||
| PLCB1 | 0 | 0 | |||
| PLCG1 | 0 | 0 | |||
| PLCG2 | 慢性淋巴细胞白血病 | 1 | 1 | ||
| PLEKHA1 | 0 | 0 | |||
| PLEKHH2 | 0 | 0 | |||
| PLK1 | 0 | 0 | |||
| PLK2 | 0 | 0 | |||
| PLPPR4 | 0 | 0 | |||
| PLXNA1 | 0 | 0 | |||
| PLXNB2 | 0 | 0 | |||
| PMAIP1 | 0 | 0 | |||
| PML | 急性早幼粒细胞白血病 | All-trans Retinoic Acid, | 三氧化二砷, | 4 | 7 |
| PMS1 | 0 | 0 | |||
| PMS2 | 多形性胶质母细胞瘤,林奇综合征 | 纳武单抗（纳武利尤单抗）, | 2 | 2 | |
| PNO1 | 0 | 0 | |||
| PNPLA3 | 0 | 0 | |||
| PNRC1 | 0 | 0 | |||
| POLD1 | 肺腺癌,非小细胞肺癌 | 派姆单抗（帕博利珠单抗）, | 3 | 3 | |
| POLD3 | 0 | 0 | |||
| POLDIP2 | 0 | 0 | |||
| POLE | 结直肠癌,子宫内膜癌,多形性胶质母细胞瘤 | 派姆单抗（帕博利珠单抗）, | 4 | 5 | |
| POLE4 | 肺腺癌 | 派姆单抗（帕博利珠单抗）, | 1 | 1 | |
| POLG | 0 | 0 | |||
| POLH | 0 | 0 | |||
| POLM | 0 | 0 | |||
| POLN | 0 | 0 | |||
| POLQ | 0 | 0 | |||
| POLR2B | 0 | 0 | |||
| POM121 | 0 | 0 | |||
| POM121L12 | 0 | 0 | |||
| POT1 | 慢性淋巴细胞白血病 | 1 | 1 | ||
| POTEG | 0 | 0 | |||
| POU2AF1 | 0 | 0 | |||
| POU5F1 | 结肠癌 | 奥沙利铂, | 1 | 1 | |
| PPARD | 0 | 0 | |||
| PPARG | 0 | 0 | |||
| PPHLN1 | 0 | 0 | |||
| PPM1D | 0 | 0 | |||
| PPP1R15A | 结直肠癌 | 贝伐单抗,FOLFIRI Regimen, | 1 | 1 | |
| PPP1R17 | 0 | 0 | |||
| PPP2R1A | 0 | 0 | |||
| PPP2R2A | 0 | 0 | |||
| PPP2R5B | 0 | 0 | |||
| PPP4R2 | 0 | 0 | |||
| PPP6C | 0 | 0 | |||
| PRAM1 | 0 | 0 | |||
| PRCC | 0 | 0 | |||
| PRDM1 | 弥漫性大B细胞淋巴瘤 | 1 | 2 | ||
| PRDM14 | 0 | 0 | |||
| PRDM16 | 0 | 0 | |||
| PREX2 | 黑色素瘤 | 维莫非尼, | 1 | 1 | |
| PRF1 | 0 | 0 | |||
| PRIM2 | 0 | 0 | |||
| PRKAA1 | 0 | 0 | |||
| PRKAA2 | 癌症 | ACLY SiRNA, | 1 | 1 | |
| PRKACA | 肝细胞纤维板层癌,肝细胞混合纤维板层癌 | 1 | 4 | ||
| PRKACB | 0 | 0 | |||
| PRKACG | 0 | 0 | |||
| PRKAR1A | 0 | 0 | |||
| PRKCA | 0 | 0 | |||
| PRKCB | 成人T细胞白血病 | 1 | 1 | ||
| PRKCE | 0 | 0 | |||
| PRKCG | 0 | 0 | |||
| PRKCI | 0 | 0 | |||
| PRKD1 | 0 | 0 | |||
| PRKDC | 0 | 0 | |||
| PRKN | 0 | 0 | |||
| PROKR2 | 0 | 0 | |||
| PROM1 | 肝细胞癌 | 索拉非尼, | 1 | 1 | |
| PRPF39 | 0 | 0 | |||
| PRPF40B | 0 | 0 | |||
| PRRT2 | 0 | 0 | |||
| PRRX1 | 0 | 0 | |||
| PRSS1 | 0 | 0 | |||
| PRSS3 | 0 | 0 | |||
| PRSS8 | 0 | 0 | |||
| PRX | 0 | 0 | |||
| PSG2 | 0 | 0 | |||
| PSIP1 | 0 | 0 | |||
| PSMB1 | 0 | 0 | |||
| PSMB2 | 0 | 0 | |||
| PSMB5 | 0 | 0 | |||
| PSMB8 | 胃腺癌 | 1 | 1 | ||
| PSMD4 | 乳腺癌,结直肠癌 | 卡非佐米,他拉唑帕尼, | 2 | 2 | |
| PTCH1 | 基底细胞癌,脑髓母细胞瘤,癌,髓母细胞瘤 | 索尼德吉,维莫德吉, | 7 | 8 | |
| PTCH2 | 0 | 0 | |||
| PTEN | 膀胱癌,乳腺癌,癌症,结直肠癌,子宫内膜癌,子宫内膜增生,胃腺癌,多形胶质母细胞瘤,头颈癌,头颈鳞状细胞癌,Her2受体阳性乳腺癌,黑色素瘤,卵巢癌,胰腺癌,前列腺癌腺癌,前列腺癌,pten错构瘤肿瘤综合征,皮肤黑色素瘤,实体瘤,胃癌,甲状腺癌 | Tanespimycin,Capivasertib,AZD8186,Buparlisib,阿培利司,西妥昔单抗,Chemotherapy,达可替尼,EGFR Inhibitor,恩扎鲁胺,厄洛替尼,依维莫司,氟维司群,吉非替尼,Uprosertib,Ipatasertib,拉帕替尼,LY294002,MK-2206,MTOR Inhibitors,帕尼单抗,PD184352,Perifosine,Pictilisib,Torkinib,Ridaforolimus,Taselisib,西罗莫司,曲妥珠单抗,维莫非尼, | 卡铂,顺铂,多西他赛,紫杉醇, | 8 | 53 |
| PTGIS | 0 | 0 | |||
| PTGS1 | 0 | 0 | |||
| PTGS2 | 结直肠癌 | 阿司匹林, | 1 | 1 | |
| PTK2 | 0 | 0 | |||
| PTK2B | 小儿B细胞急性淋巴细胞白血病 | 2 | 2 | ||
| PTK6 | 0 | 0 | |||
| PTP4A1 | 0 | 0 | |||
| PTP4A3 | 结直肠癌 | 西妥昔单抗, | 1 | 1 | |
| PTPN11 | 少年骨髓单核细胞白血病,喉癌,毛细胞星形细胞瘤 | 3 | 3 | ||
| PTPN12 | 三受体阴性乳腺癌 | 克唑替尼,舒尼替尼, | 1 | 1 | |
| PTPN13 | 0 | 0 | |||
| PTPN2 | 0 | 0 | |||
| PTPN22 | 0 | 0 | |||
| PTPN6 | 肝细胞癌 | 1 | 1 | ||
| PTPRB | 血管肉瘤 | 舒尼替尼, | 1 | 1 | |
| PTPRD | 骨尤文氏肉瘤,头颈癌 | 西妥木单抗,JSI-124,R1507, | 2 | 2 | |
| PTPRF | 非小细胞肺癌 | Erlotinib Hydrochloride, | 1 | 2 | |
| PTPRJ | 0 | 0 | |||
| PTPRK | 0 | 0 | |||
| PTPRO | 0 | 0 | |||
| PTPRS | 0 | 0 | |||
| PTPRT | 头颈部鳞状细胞癌 | JSI-124,Stattic, | 1 | 1 | |
| PTPRU | 0 | 0 | |||
| PTPRZ1 | 0 | 0 | |||
| PTTG1 | 脑膜瘤 | 1 | 1 | ||
| PURA | 0 | 0 | |||
| PXDNL | 肺腺癌 | 派姆单抗（帕博利珠单抗）, | 1 | 1 | |
| QKI | 0 | 0 | |||
| RAB35 | 0 | 0 | |||
| RABGAP1L | 0 | 0 | |||
| RAC1 | 黑色素瘤 | 达拉非尼,维莫非尼, | 1 | 1 | |
| RAC2 | 0 | 0 | |||
| RAC3 | 0 | 0 | |||
| RAD21 | 0 | 0 | |||
| RAD23B | 肉瘤 | 伏立诺他, | 1 | 1 | |
| RAD50 | 输尿管小细胞癌 | AZD7762, | 伊立替康, | 1 | 1 |
| RAD51 | 0 | 0 | |||
| RAD51B | 0 | 0 | |||
| RAD51C | 0 | 0 | |||
| RAD51D | 乳腺癌 | 1 | 1 | ||
| RAD52 | 0 | 0 | |||
| RAD54B | 0 | 0 | |||
| RAD54L | 0 | 0 | |||
| RAF1 | 黑色素瘤,皮肤黑色素瘤 | 索拉非尼,维莫非尼, | 卡铂,紫杉醇, | 2 | 2 |
| RAI14 | 0 | 0 | |||
| RANBP2 | 0 | 0 | |||
| RARA | 0 | 0 | |||
| RARB | 0 | 0 | |||
| RARG | 0 | 0 | |||
| RASA1 | 非小细胞肺癌 | 曲美替尼, | 1 | 1 | |
| RASGEF1A | 0 | 0 | |||
| RASGRP1 | 0 | 0 | |||
| RASSF1 | 0 | 0 | |||
| RASSF8 | 0 | 0 | |||
| RB1 | 乳腺癌,雌激素受体阳性乳腺癌,多形胶质母细胞瘤,非小细胞肺癌,小细胞肺癌,胰腺腺癌,膀胱癌 | 阿培利司,Chemotherapy,丝裂霉素C,哌柏西利,帕博西尼,帕博西林,瑞博西尼, | 氟尿嘧啶,多柔比星,吉西他滨, | 7 | 9 |
| RBBP8 | 0 | 0 | |||
| RBI | 0 | 0 | |||
| RBL1 | 0 | 0 | |||
| RBM10 | 0 | 0 | |||
| RBM27 | 0 | 0 | |||
| RECQL | 0 | 0 | |||
| RECQL4 | 0 | 0 | |||
| REEP5 | 0 | 0 | |||
| REG3A | 0 | 0 | |||
| REL | 弥漫性大B细胞淋巴瘤 | 1 | 1 | ||
| RELA | 0 | 0 | |||
| RELN | 0 | 0 | |||
| RET | 乳腺癌,癌症,雌激素受体阴性乳腺癌,胃肠道间质瘤,肺腺癌,肺癌,非小细胞肺癌,乳头状腺癌,乳头状甲状腺癌,甲状腺癌,甲状腺髓样癌 | 阿来替尼，艾乐替尼,阿昔替尼,AZD1480,卡博替尼,依维莫司,INK128,仑伐替尼 乐伐替尼,塞尔帕替尼,尼达尼布,NVP-AST487,帕纳替尼/普纳替尼/波纳替尼,瑞戈非尼,索拉非尼,舒尼替尼,凡德他尼, | 莫特塞尼, | 13 | 36 |
| REV1 | 0 | 0 | |||
| REV3L | 0 | 0 | |||
| RFC1 | 0 | 0 | |||
| RFC4 | 0 | 0 | |||
| RGPD3 | 0 | 0 | |||
| RGS3 | 0 | 0 | |||
| RHBDF2 | 0 | 0 | |||
| RHEB | 肾癌 | 西罗莫司, | 1 | 1 | |
| RHOA | 胃癌 | 1 | 1 | ||
| RHOH | 0 | 0 | |||
| RHOT1 | 0 | 0 | |||
| RHPN1 | 0 | 0 | |||
| RIC1 | 0 | 0 | |||
| RICTOR | 胃腺癌,肺腺癌,小细胞肺癌 | AZD2014,AZD8055,CC-223,INK128,Sapanisertib, | 1 | 3 | |
| RINT1 | 0 | 0 | |||
| RIPK2 | 0 | 0 | |||
| RIPK4 | 0 | 0 | |||
| RIT1 | 子宫内膜癌,肺腺癌 | Pictilisib,司美替尼, | 2 | 2 |
Copyright © 2020 基因医生
京ICP备13051264号-65 
京公网安备
11010802036025号